How has Nektar Therapeutics's long-term marketable securities changed year-over-year?

Nektar Therapeutics's long-term marketable securities increased by 7973.0% year-over-year, from $2.02M to $162.99M.

What is the long-term trend for Nektar Therapeutics's long-term marketable securities?

Over 5 years (2020 to 2025), Nektar Therapeutics's long-term marketable securities has grown at a -100.0% compound annual growth rate (CAGR), from $136.66M to $0.

Nektar Therapeutics NKTR Long-term marketable securities

Long-term marketable securities at other companies

Kymera TherapeuticsKYMR

——

Arcus BiosciencesRCUS

——

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.19B+1,531%

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's long-term marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's long-term marketable securities?: Nektar Therapeutics (NKTR) reported long-term marketable securities of $162.99M in Q1 2026.
How has Nektar Therapeutics's long-term marketable securities changed year-over-year?: Nektar Therapeutics's long-term marketable securities increased by 7973.0% year-over-year, from $2.02M to $162.99M.
What is the long-term trend for Nektar Therapeutics's long-term marketable securities?: Over 5 years (2020 to 2025), Nektar Therapeutics's long-term marketable securities has grown at a -100.0% compound annual growth rate (CAGR), from $136.66M to $0.